Solid Biosciences (NASDAQ:SLDB - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.10), Zacks reports.
Solid Biosciences Price Performance
Shares of Solid Biosciences stock traded down $0.33 during midday trading on Monday, reaching $5.09. The company had a trading volume of 1,744,451 shares, compared to its average volume of 2,905,388. The firm has a market cap of $388.46 million, a PE ratio of -1.67 and a beta of 1.98. The stock has a fifty day moving average price of $4.07 and a 200 day moving average price of $5.53. Solid Biosciences has a fifty-two week low of $2.88 and a fifty-two week high of $15.05.
Analyst Ratings Changes
Several analysts have recently weighed in on SLDB shares. Wedbush initiated coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an "outperform" rating and a $16.00 target price on the stock. Citizens Jmp upgraded shares of Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. dropped their target price on Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 12th. Chardan Capital reaffirmed a "buy" rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Friday. Finally, Truist Financial assumed coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They set a "buy" rating and a $16.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $15.80.
View Our Latest Stock Report on SLDB
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Articles
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
